FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to field of immunology. Claimed is fully human monoclonal antibody, which binds insulin-like growth factor II (IGF-II) and has cross-reactivity to IGF-I, as well as its antigen-binding fragment. Described is molecule of nucleic acid, encoding antibody by the invention, vector and host cell for expression of antibody by the invention. Described is pharmaceutical composition, as well as conjugates for treatment and diagnostics of malignant tumour, application of antibody by the invention in medication manufacturing and method of determining level 1GF-II and IGF-I in patient's sample.
EFFECT: invention can find further application in cancer therapy.
55 cl, 27 ex, 18 tbl, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| DRUG CONJUGATES FROM MONOCLONAL CMET BINDING AGENTS AND THEIR USE | 2019 |
|
RU2813828C2 |
| BINDING PROTEINS SPECIFIC TO INSULIN-LIKE GROWTH FACTORS, AND USING THEM | 2013 |
|
RU2549703C2 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND ITS ANTIBODY-DRUG CONJUGATE | 2022 |
|
RU2814164C2 |
| ANTIBODIES AGAINST CTLA4 AND THEIR USE | 2017 |
|
RU2779312C2 |
| ANTIBODIES AND ANALYSIS METHODS FOR FOLIC ACID 1 RECEPTOR DETECTION | 2014 |
|
RU2725825C2 |
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
| ANTIBODIES AGAINST OX40 AND THEIR USE | 2017 |
|
RU2783314C2 |
| NOVEL ANTI-PD-L1 ANTIBODIES | 2016 |
|
RU2736151C2 |
| ANTIBODIES AGAINST EDB AND ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2758632C2 |
